Tevogen Bio to lead panels on AI in biopharma and healthcare economics

Tevogen Bio Holdings Inc. is set to host impactful panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference, the industry’s premier healthcare investment symposium. This renowned event brings together global industry leaders, emerging high-growth companies, innovative technology pioneers, and key members of the investment community. A key focus of the conference will be on the transformative potential of AI in biopharma, showcasing how AI-driven technologies are revolutionizing drug discovery and development. Discussions will explore how these advancements can significantly accelerate timelines, enhance accessibility for patients, and reduce operating costs. This intersection of artificial intelligence and biopharma innovation is poised to drive quicker, more efficient innovation cycles, ultimately reshaping the healthcare landscape and delivering better outcomes for patients worldwide.

Tevogen’s panels will explore critical themes shaping the future of healthcare:

1. Pioneering the Economics of Health
   This session will delve into the often-overlooked interdependencies within the healthcare ecosystem, examining how a holistic perspective can lead to transformative solutions.

2. AI in Biopharma
   Focused on the revolutionary impact of AI-driven technologies, this discussion will highlight how AI is reshaping drug discovery, accelerating development timelines, improving patient accessibility, fostering innovation, and reducing operational costs.

Distinguished Panelists:

• David Rhew, Global Chief Medical Officer and VP of Healthcare, Microsoft
• Sean Tunis, Principal, Rubix Health
• Peter Ehrhardt, Senior Partner, Simon-Kucher
• Poonam Alaigh, Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs

These discussions underscore Tevogen’s commitment to driving innovation and collaboration across the healthcare industry.